Author:
Casellas Caro Manel,Hidalgo María Jesús Cancelo,García-Erce José Antonio,Baquero Úbeda José Luis,Torras Boatella Maria Glòria,Gredilla Díaz Elena,Ruano Encinar Margarita,Martín Bayón Israel,Nicolás Picó Jordi,Arjona Berral José Eduardo,Muñoz Solano Alberto,Jiménez Merino Silvia,Cerezales Mónica,Cuervo Jesús
Abstract
Abstract
Background
The objective of the FeminFER project was to assess the value of ferric carboxymaltose following a multicriteria decision analysis in obstetrics and gynaecology in Spain.
Methods
Ferric carboxymaltose (FCM) and ferrous sulphate were evaluated using the EVIDEM framework. Ten stakeholders participated to collect different perspectives. The framework was adapted considering evidence retrieved with a PICO-S search strategy and grey literature. Criteria/subcriteria were weighted by level of relevance and an evidence-based decision-making exercise was developed in each criterion; weights and scores were combined to obtain the value of intervention relative to each criterion/subcriterion, that were further combined into the Modulated Relative Benefit-Risk Balance (MRBRB).
Results
The most important criterion favouring FCM was Compared Efficacy/Effectiveness (0.183 ± 0.07), followed by Patient Preferences (0.059 ± 0.10). Only Direct medical costs criterion favoured FS (-0.003 ± 0.03). MRBRB favoured FCM; 0.45 ± 0.19; in a scale from -1 to + 1.
Conclusions
In conclusion, considering the several criteria involved in the decision-making process, participants agreed with the use of FCM according to its MRBRB.
Funder
Vifor Pharma España S.L.U.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献